MedPath

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia

• The FDA has granted accelerated approval to asciminib for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. • The approval was based on Phase 3 trial data involving 405 patients, demonstrating a major molecular response rate of 68% at 48 weeks with asciminib. • This response rate was compared to 49% for standard tyrosine kinase inhibitors in the same trial, highlighting asciminib's potential as a first-line treatment. • Common adverse reactions associated with asciminib included musculoskeletal pain, rash, and fatigue, as reported in the agency's news release.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. This decision marks a significant advancement in the therapeutic landscape for CML, offering a new first-line treatment option for patients.
The approval was primarily based on data derived from a Phase 3 clinical trial that enrolled 405 patients. The study results indicated a major molecular response (MMR) rate of 68% at 48 weeks in patients treated with asciminib, compared to a 49% MMR rate in those receiving standard tyrosine kinase inhibitors (TKIs). This statistically significant difference underscores the potential of asciminib as an effective initial therapy for CML.
Common adverse reactions reported during the clinical trial included musculoskeletal pain, rash, and fatigue. These side effects are important considerations for clinicians when prescribing asciminib and managing patient care.
The FDA's approval utilized the Real-Time Oncology Review (RTOR) pilot program, which aims to streamline the review process and expedite the availability of promising cancer treatments to patients in need. This accelerated pathway reflects the urgency and importance of providing new options for individuals diagnosed with CML.

Clinical Trial Details

The Phase 3 trial compared asciminib to standard TKIs in newly diagnosed Ph+ CML patients. The primary endpoint was MMR at 48 weeks. Secondary endpoints included safety and tolerability. The patient population consisted of adults with confirmed Ph+ CML in the chronic phase who had not previously received TKI therapy.

Implications for CML Treatment

This approval offers a new treatment choice for patients with Ph+ CML. Asciminib's novel mechanism of action, as a STAMP inhibitor, provides an alternative approach to managing the disease, particularly for patients who may not respond optimally to traditional TKIs or experience significant side effects. The accelerated approval is contingent upon further confirmatory trials to verify the clinical benefit.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Asciminib as First-Line Treatment for Chronic Myeloid Leukemia

The FDA has granted accelerated approval to asciminib (Scemblix) as a first-line treatment for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML).
Asciminib, a tyrosine kinase inhibitor, offers a novel mechanism of action by blocking the BCR-ABL protein at a unique site, potentially improving efficacy and tolerability.

FDA Approves Novartis' Scemblix as First-Line Treatment for Chronic Myeloid Leukemia

The FDA granted accelerated approval to Scemblix (asciminib) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
The approval was based on the Phase 3 ASC4FIRST trial, which demonstrated superior major molecular response rates at week 48 compared to standard tyrosine kinase inhibitors.

FDA Approves Asciminib (Scemblix) for Newly Diagnosed Chronic Myeloid Leukemia

The FDA has granted accelerated approval to asciminib for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase.
Asciminib, a first-in-class STAMP inhibitor, was approved based on the ASC4First trial results, which demonstrated superior major molecular response (MMR) rates at 48 weeks compared to TKIs.

FDA Approves Asciminib (Scemblix) for Newly Diagnosed Philadelphia Chromosome-Positive CML

The FDA granted accelerated approval to asciminib (Scemblix) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase.
The approval was based on the phase 3 ASC4FIRST trial, which compared asciminib to investigator-selected tyrosine kinase inhibitors (TKIs) in patients with Ph-positive CML.

FDA Approves Asciminib (Scemblix) as First-Line Treatment for Ph+ Chronic Myeloid Leukemia

The FDA granted accelerated approval to asciminib for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
The approval was based on the ASC4FIRST trial, which demonstrated a significantly higher major molecular response rate at 48 weeks compared to standard TKIs.

FDA Approves Asciminib (Scemblix) as First-Line Treatment for Ph+ CML-CP

The FDA granted accelerated approval to asciminib for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
Asciminib is the first CML treatment that specifically targets the ABL myristoyl pocket, offering a novel mechanism of action compared to existing TKIs.

FDA Approves Scemblix (asciminib) for Newly Diagnosed Chronic Myeloid Leukemia

The FDA granted accelerated approval to Scemblix (asciminib) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.
The approval was based on the ASC4FIRST trial, which demonstrated a significantly higher major molecular response rate at 48 weeks with Scemblix compared to other tyrosine kinase inhibitors.

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia

The FDA has granted accelerated approval to asciminib (Scemblix) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
Asciminib, a BCR::ABL1 kinase inhibitor, showed a major molecular response (MMR) rate of 68% at 48 weeks in the ASC4FIRST trial.

FDA Approves Asciminib for Newly Diagnosed Philadelphia Chromosome-Positive CML

The FDA granted accelerated approval to asciminib for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Asciminib demonstrated a major molecular response (MMR) rate of 68% at 48 weeks, compared to 49% in patients treated with standard tyrosine kinase inhibitors (TKIs).

FDA Approves Asciminib (Scemblix) for Newly Diagnosed Philadelphia Chromosome-Positive CML

The FDA has granted accelerated approval to asciminib (Scemblix) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
The approval was based on the ASC4FIRST trial, a randomized, active-controlled, open-label study that compared asciminib to investigator's choice of tyrosine kinase inhibitor (TKI).

Reference News

[1]
FDA grants accelerated approval for leukemia treatment - Becker's Hospital Review
beckershospitalreview.com · Oct 31, 2024

FDA granted accelerated approval to asciminib for adults with newly diagnosed Philadelphia chromosome-positive chronic m...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy